Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.

Cooper Consumer Health has closed its acquisition of Viatris' OTC business as it commits to divesting the rights to infant laxative medicine Bebegel and earwax removal product Otowaxol in certain markets.

The Indian player made another high-level deal that grants it rights to nicotine replacement therapies in over 30 countries, following on from its recent announcements with Nestlé.

“The game is still totally open,” said Sanofi CFO François-Xavier Roger in response to questions about how the company intends to separate its Consumer Healthcare business. The comments came as Sanofi reported its Q2 results.

Reckitt has designated its Mead Johnson infant nutrition and home care businesses as non-core operations. The company will now reorganize to sharpen its focus on the consumer health and hygiene markets in the pursuit of sustainable, long-term growth.

A round-up of the latest appointments in Europe's health and wellness industries: Perrigo makes management changes; European Commission president re-elected; EFSA appoints new members to scientific panels.

“The game is still totally open,” said Sanofi CFO François-Xavier Roger in response to questions about how the company intends to separate its Consumer Healthcare business. The comments came as Sanofi reported its Q2 results.

Reckitt has designated its Mead Johnson infant nutrition and home care businesses as non-core operations. The company will now reorganize to sharpen its focus on the consumer health and hygiene markets in the pursuit of sustainable, long-term growth.

Analysts tracking consumer health product firms in the US anticipatevApril-June results lower than a year ago across most businesses. While some results will be lower on comparisons with strong growth in 2023, others will reflect a slow allergy season, retailers’ inventories remaining high as consumer spending slows or firms continuing to recover from supply chain problems.

Firms can be more forceful in disputes with FDA now that Supreme Court has eliminated Chevron deference. Questions around whether an evidentiary standard has been met may be ripe for challenge, legal experts said, but they also caution that sponsors will face more uncertainty.

The Supreme Court’s 6-3 ruling is expected to have a minimal impact on drug approvals and other scientific determinations, but matters steeped in the interpretation of regulation and statute, such as marketing exclusivity, could face a heightened risk of challenge, legal experts say.

The unanimous decision that the Alliance for Hippocratic Medicine lacks standing to challenge the FDA’s relaxation of the abortion pill REMS leaves unclear whether the court would have deferred to the agency’s expertise on the merits.